No. 23-799

Magellan Technology, Inc. v. Food and Drug Administration

Lower Court: Second Circuit
Docketed: 2024-01-24
Status: Denied
Type: Paid
Amici (1)Relisted (4) Experienced Counsel
Tags: administrative-procedure-act agency-rulemaking arbitrary-and-capricious circuit-split comparative-efficacy electronic-nicotine-delivery-systems ends-products fda-regulation marketing-authorization reliance-interests youth-access
Key Terms:
AdministrativeLaw
Latest Conference: 2025-04-17 (distributed 4 times)
Question Presented (AI Summary)

Whether FDA's denial of Petitioner's marketing applications for flavored ENDS was arbitrary and capricious

Question Presented (from Petition)

QUESTION PRESENTED This case presents a circuit split on an important matter—whether FDA’s denial of hundreds of thousands of marketing applications for electronic nicotine delivery systems (also known as “ENDS” and “e-cigarettes”), including Petitioner’s applications, was arbitrary and _ capricious under _ the Administrative Procedure Act. FDA denied the applications, all of which were for “flavored” ENDS (i.e., ENDS flavored to taste like something other than tobacco) solely because the applications did not include certain types of studies showing that the flavored ENDS are more effective than tobaccoflavored ENDS in helping cigarette smokers quit or reduce smoking. But FDA had not previously informed Petitioner (or the public) that such studies would be required for marketing authorization. Moreover, for the “sake of efficiency,” FDA ignored other evidence in all applications for flavored ENDS—detailed plans to limit youth exposure and access to the products—that the agency had previously said would be “critical” for marketing authorization. While the court below (and some other circuits) found FDA’s actions were not arbitrary and capricious, the Fifth Circuit (sitting en banc) and the Eleventh Circuit have found FDA’s actions were arbitrary and capricious. The question presented is: Whether FDA’s denial of Petitioner’s marketing applications for flavored ENDS was arbitrary and capricious where FDA based the denial solely on a previously unannounced requirement for certain types of studies and where FDA ignored other evidence in ii the applications that FDA previously said was “critical” for marketing authorization.

Docket Entries

2025-04-21
Petition DENIED.
2025-04-14
DISTRIBUTED for Conference of 4/17/2025.
2024-06-28
DISTRIBUTED for Conference of 7/1/2024.
2024-06-04
DISTRIBUTED for Conference of 6/20/2024.
2024-04-16
Rescheduled.
2024-04-10
DISTRIBUTED for Conference of 4/26/2024.
2024-03-25
Brief of respondent United States Food and Drug Administration in opposition filed.
2024-02-23
Brief amici curiae of E-Cigarette Businesses and Trade Associations filed.
2024-01-26
Motion to extend the time to file a response is granted and the time is extended to and including March 25, 2024
2024-01-25
Motion to extend the time to file a response from February 23, 2024 to March 25, 2024, submitted to The Clerk.
2024-01-22
Petition for a writ of certiorari filed. (Response due February 23, 2024)
2023-11-17
Application (23A421) granted by Justice Sotomayor extending the time to file until January 22, 2024.
2023-11-13
Application (23A421) to extend the time to file a petition for a writ of certiorari from November 23, 2023 to January 22, 2024, submitted to Justice Sotomayor.

Attorneys

E-Cigarette Businesses and Trade Associations
Eric Philip GottingKeller and Heckman LLP, Amicus
Eric Philip GottingKeller and Heckman LLP, Amicus
Magellan Technology, Inc.
Eric N. HeyerThompson Hine LLP, Petitioner
Eric N. HeyerThompson Hine LLP, Petitioner
United States Food and Drug Administration
D. John SauerSolicitor General, Respondent
D. John SauerSolicitor General, Respondent
Elizabeth B. Prelogar — Respondent
Sarah M. HarrisActing Solicitor General, Respondent